DOCSLIB.ORG

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Review Thieme Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Authors C. Hiemke1, 2, N. Bergemann3, H. W. Clement4, A. Conca5, J. Deckert6, K. Domschke7, G. Eckermann8, K. Egberts9, M. Gerlach9, C. Greiner10, G. Gründer11, E. Haen12, U. Havemann-Reinecke13, G. Hefner14, R. Helmer15, G. Janssen16, E. Jaquenoud17, G. Laux18, T. Messer19, R. Mössner20, M. J. Müller21, M. Paulzen11, B. Pfuhlmann22, P. Riederer6, A. Saria23, B. Schoppek24, G. Schoretsanitis25, M. Schwarz26, M. Silva Gracia12, B. Stegmann12, W. Steimer27, J. C. Stingl10, M. Uhr28, S. Ulrich29, S. Unterecker6, R. Waschgler30, G. Zernig23, 31, G. Zurek32, P. Baumann33 Affiliations 19 Danuviuskliniken, Psychiatric Hospital, Pfaffenhofen, 1 Department of Psychiatry and Psychotherapy, University Germany Medical Center of Mainz, Mainz, Germany 20 Department of Psychiatry and Psychotherapy, University 2 Institute of Clinical Chemistry and Laboratory Medicine, of Tübingen, Tübingen, Germany University Medical Center of Mainz, Mainz, Germany 21 Psychiatric Hospitals Oberberggruppe, Berlin, Germany 3 Kitzberg Hospitals, Center for Psychosomatic Medicine 22 Psychiatric Hospital Weisser Hirsch, Dresden, Germany and Psychotherapy, Bad Mergentheim, Germany 23 Experimental Psychiatry Unit, Department of Psychiatry 4 Department of Child and Adolescent Psychiatry, 1, Medical University of Innsbruck, Innsbruck, Austria University of Freiburg, Freiburg, Germany 24 kbo-Isar-Amper Klinikum München-Ost, Psychiatric 5 Servizio Psichiatrico del Comprensorio Sanitario di Hospital, Munich-Haar, Germany Bolzano, Bolzano, Italy 25 Department of Psychiatry, University of Bern, Bern, 6 Department of Psychiatry, Psychotherapy and Psychoso- Switzerland matics, University Hospital of Würzburg, Germany 26 Department of Laboratory Medicine, Ludwig Maximilian 7 Department of Psychiatry and Psychotherapy, Medical University, Munich, Germany Center - University of Freiburg, Faculty of Medicine, 27 Institute of Clinical Chemistry and Pathobiochemistry, University of Freiburg, Freiburg, Germany Technical University Munich, Munich, Germany 8 Psychiatric Hospital, Kaufbeuren, Germany 28 Max Planck Institute of Psychiatry, Munich, Germany 9 Department of Child and Adolescent Psychiatry, 29 Aristo Pharma GmbH, Berlin, Germany Psychosomatics and Psychotherapy, Center of Mental 30 Psychiatric Hospital, Feldkirch, Austria Health, University Hospital of Würzburg, Germany 31 Private Practice for Psychotherapy and Court-Certified 10 Federal Institute for Drugs and Medical Devices (BfArM), Witness, Hall in Tirol, Austria Bonn, Germany 32 Medical Laboratory Bremen, Bremen, Germany 11 Department of Psychiatry, Psychotherapy and Psychoso- 33 Department of Psychiatry, University of Lausanne, matics, RWTH Aachen University, Aachen, and JARA – Prilly-Lausanne, Switzerland Translational Brain Medicine, Aachen, Germany 12 Clinical Pharmacology, Department of Psychiatry and Psycho- Key words therapy and Department of Pharmacology and Toxicology, antidepressant drugs, antiepileptic drugs, antiparkinson University of Regensburg, Regensburg, Germany drugs, antipsychotic drugs, concentration in blood, This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 13 Department of Psychiatry and Psychosomatics, University consensus guidelines, drug analysis, genotyping, neurologic of Göttingen, Göttingen, Germany drugs, pharmacogenetics, pharmacokinetics, phenotyping, 14 Psychiatric Hospital, Vitos Klinik, Eichberg, Eltville, Germany plasma concentration, psychiatric drugs, reference range, 15 Center of Epilepsy, Bielefeld, Germany serum concentration, therapeutic drug monitoring, 16 Medical Laboratory Stein, Limbach Group, therapeutic window Mönchengladbach, Germany 17 Psychiatric Hospital, Königsfelden, Brugg, Aargau, received 15.05.2017 Switzerland revised 08.07.2017 18 Institute of Psychological Medicine, Haag in Oberbayern, accepted 10.07.2017 Germany Hiemke C et al. Consensus Guidelines for Therapeutic … Pharmacopsychiatry 2018; 51: 9–62 9 Review Thieme Bibliography 2. Drug Concentrations in Blood to Guide DOI http://dx.doi.org/10.1055/s-0043-116492 Neuropsychopharmacotherapy 22 Published online: 14.9.2017 2.1 The therapeutic reference range 22 2.1.1 Estimation of the lower limit of the therapeutic Pharmacopsychiatry 2018; 51: 9–62 reference range 33 © Georg Thieme Verlag KG Stuttgart · New York 2.1.2 Estimation of the upper limit of the therapeutic ISSN 0176-3679 reference range 33 2.1.3 From population-based to subject-based reference values 33 Correspondence 2.1.4 Laboratory alert level 34 C. Hiemke, PhD, Univ.-Prof. 2.2 The dose-related reference range 34 Department of Psychiatry and Psychotherapy 2.3 Concentration to dose ratio 44 University Medical Center, Mainz 2.4 Metabolite to parent compound ratios 44 Untere Zahlbacher Str. 8 2.5 Probe drug phenotyping 46 D-55101 Mainz 2.6 Indications for measuring drug concentrations in blood 47 Germany 2.7 Recommendations for measuring drug [email protected] concentrations in blood 50 3. Practical Aspects of TDM in Psychiatry and Neurology 52 Abstract 3.1 TDM request for quantification of drug concentrations in blood 52 Therapeutic drug monitoring (TDM) is the quantification and 3.2 Specimen collection 53 interpretation of drug concentrations in blood to optimize 3.2.1 Blood sample collection 53 pharmacotherapy. It considers the interindividual variability of 3.2.2 Oral fluid for TDM 54 pharmacokinetics and thus enables personalized pharmaco- 3.3 Storage and shipment of blood samples 55 therapy. In psychiatry and neurology, patient populations that 3.4 Laboratory measurements 55 may particularly benefit from TDM are children and adoles- 3.5 Computing of trough steady-state concentrations 56 cents, pregnant women, elderly patients, individuals with intel- 3.6 Interpretation and communication of results and lectual disabilities, patients with substance abuse disorders, recommendations 56 forensic psychiatric patients or patients with known or sus- 3.6.1 How to use the TDM guidelines for interpretation of results – cases 57 pected pharmacokinetic abnormalities. Non-response at ther- 3.7 Pharmacogenetic tests in addition to TDM 59 apeutic doses, uncertain drug adherence, suboptimal tolerabil- 3.8 Clinical decision making 60 ity, or pharmacokinetic drug-drug interactions are typical 3.9 Cost-effectiveness of TDM 61 indications for TDM. However, the potential benefits of TDM to 4. Conclusions and Perspectives 61 optimize pharmacotherapy can only be obtained if the method References 62 is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid informa- tion on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie Abbreviations (AGNP) issued their first guidelines for TDM in psychiatry in BBB blood-brain-barrier 2004. After an update in 2011, it was time for the next update. C/D concentration to dose ratio Following the new guidelines holds the potential to improve CL total clearance neuropsychopharmacotherapy, accelerate the recovery of CL/F apparent total clearance many patients, and reduce health care costs. Cav average concentration Cmax maximal concentration Cmin trough or minimal concentration CYP cytochrome P450 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Table of Contents DRC dose-related concentration EMA European Medicines Agency Abbreviations 10 F bioavailability (fraction absorbed) Background 11 FDA Food and Drug Administration Objectives of the Consensus Document 12 GeKO German Commission Genetic Testing Preparation of the Consensus Document 12 MPR metabolite to parent compound ratio 1. Pharmacokinetics and pharmacogentics 12 PET positron emission tomography 1.1 Pharmacokinetic aspects 12 1.1.1 Absorption, distribution and elimination of P-gp P-glycoprotein neuropsychiatric drugs 12 t1/2 elimination half-life 1.1.2 Drug concentrations in blood 17 TDM therapeutic drug monitoring 1.1.3 Drug concentrations in brain and cerebrospinal fluid 19 tmax time of maximal drug concentrations 1.2 Pharmacogenetic aspects 20 tmin time of minimal drug concentration 10 Hiemke C et al. Consensus Guidelines for Therapeutic … Pharmacopsychiatry 2018; 51: 9–62 Pharmacodynamics Pharmacokinetics Interactions with Absorption neurotransmitter receptors, Distribution transporters, metabolizing Metabolism enzymes and signal Excretion transduction systems Drug Drug Prescribed Drug concentration concentration dose effects in blood in brain Age, gender, disease, Neurogenesis, brain maturation, Drug lipophilicity, pregnancy, pharmacokinetic pharmacodynamic genotype drug transporter affinity, genotype, adherence, (neurotransmitter receptors, re- blood-brain-barrier medication error, interactions uptake transporters and permeability with other drugs, diet, smoking metabolizing enzymes) ▶Fig. 1 From prescribed dose to drug effects modulated by multiple factors leading to marked pharmacokinetic and pharmacodynamic variability. of a drug’s concentration in blood plasma or serum to titrate the Background dosage of individual patients to a drug concentration in blood that For the treatment of psychiatric and neurologic patients, more than is associated with the highest possible probability of response and 200 drugs are available which have been discovered and developed a low risk of adverse drug reactions/toxicity. Moreover, TDM has during the last 60 years
Load more

Recommended publications
  • 1: Clinical Pharmacokinetics 1
    1: CLINICAL PHARMACOKINETICS 1 General overview: clinical pharmacokinetics, 2 Pharmacokinetics, 4 Drug clearance (CL), 6 Volume of distribution (Vd), 8 The half-life (t½), 10 Oral availability (F), 12 Protein binding (PB), 14 pH and pharmacokinetics, 16 1 Clinical pharmacokinetics General overview General overview: clinical pharmacokinetics 1 The ultimate aim of drug therapy is to achieve effi cacy without toxicity. This involves achieving a plasma concentration (Cp) within the ‘therapeutic window’, i.e. above the min- imal effective concentration (MEC), but below the minimal toxic concentration (MTC). Clinical pharmacokinetics is about all the factors that determine variability in the Cp and its time-course. The various factors are dealt with in subsequent chapters. Ideal therapeutics: effi cacy without toxicity Minimum Toxic Concentration (MTC) Ideal dosing Minimum Effective Concentration (MEC) Drug concentration Time The graph shows a continuous IV infusion at steady state, where the dose-rate is exactly appropriate for the patient’s clearance (CL). Inappropriate dosing Dosing too high in relation to the patient’s CL – toxicity likely Minimum Toxic Concentration (MTC) Minimum Effective Concentration (MEC) Dosing too low in relation to the Drug concentration patient’s CL – drug may be ineffective Time Some reasons for variation in CL Low CL High CL Normal variation Normal variation Renal impairment Increased renal blood fl ow Genetic poor metabolism Genetic hypermetabolism Liver impairment Enzyme induction Enzyme inhibition Old age/neonate 2 General overview Clinical Pharmacokinetics Pharmacokinetic factors determining ideal therapeutics If immediate effect is needed, a loading dose (LD) must be given to achieve a desired 1 concentration. The LD is determined by the volume of distribution (Vd).
    [Show full text]
  • Narrow Therapeutic Index
    Therapeutic Drug Monitoring Some drugs have a narrow therapeutic index, which means that there is only a small difference between the minimum effective concentrations and the minimum toxic concentrations in the blood. With such drugs, small increases in dose or in blood/serum concentrations could lead to toxic effects. Therapeutic drug monitoring may help to optimise treatment in cases where there is a firm relationship between the toxic/therapeutic effects and drug concentrations in whole blood/serum. A therapeutic interval has been defined for the drugs in the following tables. This is the minimum effective and maximum safe concentration for compliant patients, on stabilised regimens. Levels within these limits should prove satisfactory in most cases. Whole blood or serum drug concentrations are useful for determining patient compliance or for assessing whether or not: 1. adequate concentrations are being achieved or, 2. potentially toxic concentrations are being reached. Depending on clinical conditions, dosage adjustments may be needed when levels are outside the therapeutic interval. Therapeutic drug monitoring can also be useful when changes are made to other medications that could affect serum or whole blood concentrations and lead to a reduction in effectiveness or increased toxicity. Although plasma drug concentrations and the therapeutic interval are useful in evaluating drug therapy, they should not be the only criteria on which treatment is based. Always remember to treat the patient, not the level. Drug concentrations in serum or whole blood are only meaningful if the correct procedures are followed regarding the timing of specimens and selection of sample tube. It is vitally important to note the exact time the sample is taken and when each dose of the drug is given.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Narrow Therapeutic Index Drugs: a Clinical Pharmacological Consideration to Flecainide Juan Tamargo, Jean-Yves Le Heuzey, Phillipe Mabo
    Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide Juan Tamargo, Jean-Yves Le Heuzey, Phillipe Mabo To cite this version: Juan Tamargo, Jean-Yves Le Heuzey, Phillipe Mabo. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. European Journal of Clinical Pharmacology, Springer Verlag, 2015, 71 (5), pp.549-567. 10.1007/s00228-015-1832-0. hal-01143095 HAL Id: hal-01143095 https://hal-univ-rennes1.archives-ouvertes.fr/hal-01143095 Submitted on 16 Apr 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur J Clin Pharmacol (2015) 71:549–567 DOI 10.1007/s00228-015-1832-0 REVIEW ARTICLE Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide Juan Tamargo & Jean-Yves Le Heuzey & Phillipe Mabo Received: 5 December 2014 /Accepted: 4 March 2015 /Published online: 15 April 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract specify flecainide as an NTID. The literature review demon- Purpose The therapeutic index (TI) is the range of doses at strated that flecainide displays NTID characteristics including which a medication is effective without unacceptable adverse a steep drug dose–response relationship for safety and effica- events.
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Pharmacogenetic Testing: a Tool for Personalized Drug Therapy Optimization
    pharmaceutics Review Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization Kristina A. Malsagova 1,* , Tatyana V. Butkova 1 , Arthur T. Kopylov 1 , Alexander A. Izotov 1, Natalia V. Potoldykova 2, Dmitry V. Enikeev 2, Vagarshak Grigoryan 2, Alexander Tarasov 3, Alexander A. Stepanov 1 and Anna L. Kaysheva 1 1 Biobanking Group, Branch of Institute of Biomedical Chemistry “Scientific and Education Center”, 109028 Moscow, Russia; [email protected] (T.V.B.); [email protected] (A.T.K.); [email protected] (A.A.I.); [email protected] (A.A.S.); [email protected] (A.L.K.) 2 Institute of Urology and Reproductive Health, Sechenov University, 119992 Moscow, Russia; [email protected] (N.V.P.); [email protected] (D.V.E.); [email protected] (V.G.) 3 Institute of Linguistics and Intercultural Communication, Sechenov University, 119992 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-499-764-9878 Received: 2 November 2020; Accepted: 17 December 2020; Published: 19 December 2020 Abstract: Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician’s ability to understand the obtained results in a standardized way for each particular patient.
    [Show full text]
  • Narrow Therapeutic Index Drugs
    Quality and Bioequivalence Standards for Narrow Therapeutic Index Drugs Lawrence X. Yu, Ph.D. Deputy Director for Science and Chemistry Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration GPhA 2011 Fall Technical Workshop 1 Bioequivalence • The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administrated at the same molar dose under similar conditions in an appropriately designed study…” (21 CFR §320.1) 2 Plasma Concentration Profile Cmax 10000 AUC ln Concentration 1000 Concentration Time Tmax - time of maximum concentration 100 Time 3 0 5 10 15 20 25 Possible Outcome of BE Studies Demonstrate BE Fail to Demonstrate BIE Fail to Demonstrate BE Demonstrate BIE Demonstrate BIE 80% T/R (%) 125% 4 5 FDA 12 Year BE Data Distribution of AUCt Ratios Average difference = 3.56% 10 N = 2069 8 6 Percent of Total(%) of Percent 4 2 0 0.84 0.86 0.88 0.90 0.92 0.94 0.96 0.98 1.00 1.02 1.04 1.06 1.08 1.10 1.12 1.14 1.16 1.18 1.20 6 AUC Point Estimate (T/R) Effect of Variability on BE Studies High variability 80% T/R (%) 125% 7 Development of BE Standard for Highly Variable Drugs 4/2004 First presentation to the FDA Advisory Committee 10/2006 Second presentation to the FDA Advisory Committee 3/2007 Received the first ANDA which used the new FDA BE approach 5/2007 Critical Path Opportunities for Generic Drugs BE of HVD 1/2008 FDA OGD’s first publication on BE of HVD (Pharm.
    [Show full text]
  • Specific PET-Ligands for Selected 5-Htand GABA A-Receptor Subtypes
    Specific PET-ligands for Selected 5-HT and GABAA-Receptor Subtypes PET-Liganden mit Spezifität für definierte 5-HT und GABAA-Rezeptor-Subtypen Dissertation zur Erlangung des Grades „Doktor der Naturwissenschaften“ am Fachbereich Biologie der Fabian Debus geb. am 19.09.1976 in Frankfurt am Main Mainz, im März 2008 Erklärung Hiermit versichere ich, dass ich die vorliegende Dissertation eigenständig verfasst und keine anderen als die angegebenen Hilfsmittel verwendet habe. Die Dissertation habe ich weder als Arbeit für eine staatliche oder andere wissenschaftliche Prüfung eingereicht noch ist sie oder ein Teil dieser als Dissertation bei einer anderen Fakultät oder einem anderem Fachbereich eingereicht worden. Mainz, im März 2008 II Dekan: 1. Berichterstatter: 2. Berichterstatter: Tag der mündlichen Prüfung: 28.05.2008 III Danksagung Eine solche Schrift kann niemals als Ergebnis der Arbeit eines Einzelnen, sondern sollte immer als Resultat der Arbeit einer großen Anzahl von fleißigen Menschen betrachtet werden, die dabei mitgeholfen haben, dass aus einer Idee ein gelungenes Projekt wurde. Bei meinen beiden Betreuern, Prof. Dr. H. L. und Prof. Dr. F. R., möchte ich mich für das spannende und abwechslungsreiche Thema bedanken. Außerdem für Ihr Vertrauen und Ihre Diskussionsbereitschaft. Insbesondere Herrn Prof. Dr. H. L. möchte ich für seine Unterstützung und seine vorbildliche Betreuung danken. Ich hätte mir keinen besseren Doktorvater wünschen können und bin sehr dankbar für alles, was ich in diesen drei Jahren in seiner Arbeitsgruppe lernen durfte. Besonderer Dank gebührt der gesamten Arbeitsgruppe für Ihre herzliche Gemeinschaft und das produktive Miteinander. Im Einzelnen gebührt Frau R. Dank für das Licht im Dunkel der Bürokratie. Frau B.
    [Show full text]
  • Warfarin Sodium
    Contains Nonbinding Recommendations Draft Guidance on Warfarin Sodium This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs. Active ingredient: Warfarin Sodium Form/Route: Tablet/Oral Recommended studies: 2 studies 1. Type of study: Fasting Design: 4-way, fully replicated crossover design in-vivo Strength: 10 mg Subjects: Healthy males and nonpregnant females, general population. Additional Comments: Warfarin has a long terminal elimination half-life. Please ensure adequate washout periods between treatments in the crossover studies. For long half-life drug products, an AUC truncated to 72 hours may be used in place of AUC0-t or AUC0-∞, as described in the Guidance for Industry: “Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations”. Applicants may consider using the reference-scaled average bioequivalence approach for warfarin described below. 2. Type of study: Fed Design: 4-way, fully replicated crossover design in-vivo Strength: 10 mg Subjects: Healthy males and nonpregnant females, general population. Additional Comments: See additional comments above. See Amantadine Hydrochloride Oral Tablet guidance
    [Show full text]
  • Cardiovascular Adverse Reactions During Antidepressant Treatment
    International Journal of Neuropsychopharmacology, 2015, 1–9 doi:10.1093/ijnp/pyu080 Research Article research article Cardiovascular Adverse Reactions During Downloaded from https://academic.oup.com/ijnp/article-abstract/18/4/pyu080/664200 by guest on 02 December 2019 Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010 Christoph Josef Spindelegger, MD; Konstantinos Papageorgiou, MD; Renate Grohmann, MD; Rolf Engel, MD; Waldemar Greil, MD; Anastasios Konstantinidis, MD; Marcus Willy Agelink, MD; Stefan Bleich, MD; Eckart Ruether, MD; Sermin Toto, MD; Siegfried Kasper, MD Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria (Drs Spindelegger, Papageorgiou, Konstantinidis, and Kasper); Department of Psychiatry, Psychotherapy and Preventive Medicine, Ruhr-University of Bochum, Germany (Dr Agelink); Psychiatric Private Hospital, Sanatorium Kilchberg, Switzerland (Dr Greil); Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany (Drs Bleich and Toto); Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Germany (Drs Grohmann, Engel, Greil, and Ruether) Correspondence: Siegfried Kasper, MD, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18–20, 1090 Vienna, Austria ([email protected]) Abstract Background: Antidepressants (ADs) are known to have the potential to cause various cardiovascular adverse drug reactions (ADRs). The tricyclic antidepressants (TCAs) were first revealed to be a possible source of cardiovascular ADRs. In recent years, newer classes of ADs were also suggested to have a higher risk of cardiovascular adverse effects. In particular, the selective serotonin reuptake inhibitors (SSRIs) were suspected to have the potential to induce QTc interval prolongation, and therefore increase the risk of ventricular arrhythmia.
    [Show full text]
  • The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder
    REVIEW The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder Natalia del Campo, Samuel R. Chamberlain, Barbara J. Sahakian, and Trevor W. Robbins Through neuromodulatory influences over fronto-striato-cerebellar circuits, dopamine and noradrenaline play important roles in high-level executive functions often reported to be impaired in attention-deficit/hyperactivity disorder (ADHD). Medications used in the treatment of ADHD (including methylphenidate, dextroamphetamine and atomoxetine) act to increase brain catecholamine levels. However, the precise prefrontal cortical and subcortical mechanisms by which these agents exert their therapeutic effects remain to be fully specified. Herein, we review and discuss the present state of knowledge regarding the roles of dopamine (DA) and noradrenaline in the regulation of cortico- striatal circuits, with a focus on the molecular neuroimaging literature (both in ADHD patients and in healthy subjects). Recent positron emission tomography evidence has highlighted the utility of quantifying DA markers, at baseline or following drug administration, in striatal subregions governed by differential cortical connectivity. This approach opens the possibility of characterizing the neurobiological underpinnings of ADHD (and associated cognitive dysfunction) and its treatment by targeting specific neural circuits. It is anticipated that the application of refined and novel positron emission tomography methodology will help to disentangle the overlapping and dissociable contributions of DA and noradrenaline in the prefrontal cortex, thereby aiding our understanding of ADHD and facilitating new treatments. Key Words: Attention-deficit/hyperactivity disorder, dopamine, DA and NA in the pathophysiology of ADHD, with a focus on the frontostriatal circuits, nigrostriatal projections, noradrenaline, pos- molecular neuroimaging literature.
    [Show full text]
  • Pharmacokinetic Considerations in Antipsychotic Augmentation Strategies: How to Combine Risperidone with Low-Potency Antipsychotics
    Progress in Neuro-Psychopharmacology & Biological Psychiatry 76 (2017) 101–106 Contents lists available at ScienceDirect Progress in Neuro-Psychopharmacology & Biological Psychiatry journal homepage: www.elsevier.com/locate/pnp Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics Michael Paulzen a,b,1, Georgios Schoretsanitis a,b,f,⁎,1, Benedikt Stegmann d,ChristophHiemkeg,h, Gerhard Gründer a,b,KoenR.J.Schruerse, Sebastian Walther f, Sarah E. Lammertz a,b,EkkehardHaenc,d a Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany b JARA – Translational Brain Medicine, Aachen, Germany c Clinical Pharmacology, Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany d Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany e Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands f University Hospital of Psychiatry, Bern, Switzerland g Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Germany h Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Germany article info abstract Article history: Objectives: To investigate in vivo the effect of low-potency antipsychotics on metabolism of risperidone (RIS). Received 22 December 2016 Methods: A therapeutic drug monitoring database containing plasma concentrations of RIS and its metabolite 9-OH- Accepted 12 March 2017 RIS of 1584 patients was analyzed. Five groups were compared; a risperidone group (n = 842) and four co- med- Available online 14 March 2017 ication groups; a group co-medicated with chlorprothixene (n = 67), a group with levomepromazine (n = 32), a group with melperone (n = 46), a group with pipamperone (n = 63) and a group with prothipendyl (n = 24).
    [Show full text]